2026
Resource Highlight from CRI – The Cancer Research Institute’s Resources for Sarcoma
- What Makes Immunotherapy for Sarcoma a Promising Treatment?
- Treatment Options
- ImmunotherapyClinical Trial Finder
2025
Expression of antibody-drug conjugate targets in soft tissue sarcomas: Bertucci F, Finetti P, Mescam L, Monneur A, Frejafon A, Le Cesne A, Treilleux I, Italiano A, Brahmi M, Blay JY, Mamessier E., ESMO Open. 2025 Oct;10(10):105837. doi: 10.1016/j.esmoop.2025.105837. Epub 2025 Oct 4. PMID: 41046759; PMCID: PMC12528890.
Palliative Care for Sarcoma: How to Access Palliative Care for Sarcoma – HogoNext
NCCN 2025 Palliative Care Guidelines: Palliative Care – Guidelines Detail and Palliative Care Patient Resource Guide
NCCN Clinical Trial Guidelines: Why Should I Consider a Clinical Trial? Download a free handout on why you should consider a clinical trial: download-a-printable-handout-to-learn-more-about-clinical-trials.pdf
NCCN 2025 Treatment Guidelines and Patient Guidelines:
- Soft Tissue Sarcoma – Guidelines Detail
- NCCN Guidelines for Patients: Soft Tissue Sarcoma
- NCCN Guidelines for Patients: Bone Cancer
SARC Patient Resources: What is Bone Sarcoma?
NIH/National Cancer Institute: Patient Resource for Soft Tissue Sarcoma Treatment
Targeting developmental vulnerabilities in childhood sarcomas | Cancer and Metastasis Reviews: Volume 44, article number 72, (2025); Elise Young, Barnaby Kelly & Jason E. Cain
Dividing and Conquering Sarcomas Through Precision Oncology, Dr. Neeta Somaiah, University of Texas MD Anderson Cancer Center, Houston, TX. Presented at Miami Cancer Institute Precision Oncology Symposium.
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers, Minggui Pan,
Maggie Zhou, Lu Xie, Nam Bui & Kristen Ganjoo. Journal of Hematology & Oncology abstract: Soft tissue and bone sarcomas are a heterogenous group of uncommon mesenchymal tumors with high unmet needs for novel therapeutic and diagnostic strategies. Despite many challenges that persist, innovative therapeutics are emerging. Here we provide a review of the studies presented at the 2024 American Society of Clinical Oncology annual meeting that were focused on sarcoma.
What Is a Sarcoma ‘Specialist Center’? Multidisciplinary Research Finds an Answer, Wilson R, Reinke D, van Oortmerssen G, Gonzato O, Ott G, Raut CP, Guadagnolo BA, Haas RLM, Trent J, Jones R, Pretorius L, Felser B, Basson M, Schuster K, Kasper B. What Is a Sarcoma ‘Specialist Center’? Multidisciplinary Research Finds an Answer. Cancers (Basel). 2024 May 13;16(10):1857. doi: 10.3390/cancers16101857. PMID: 38791936; PMCID: PMC11119625. The management of sarcomas in specialist centers delivers significant benefits. In much of the world, specialists are not available, and the development of expertise is identified as a major need. However, the terms ‘specialist’ or ‘expert’ center are rarely defined. Our objective is to offer a definition for patient advocates and a tool for healthcare providers to underpin improving the care of people with sarcoma.
Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma, Ashling Wahner, OncLive, January 18, 2025. Key Takeaways – The trial’s findings suggest further optimization of immunotherapy could enhance therapeutic effects in soft tissue sarcoma treatment. Pembrolizumab addition to radiotherapy and surgery improved 2-year DFS in grade 3, stage III soft tissue sarcoma patients, achieving a 67% DFS rate versus 52% without pembrolizumab. The SU2C-SARC032 trial demonstrated pembrolizumab’s potential as a new treatment option for resectable, intermediate- or high-grade undifferentiated pleomorphic sarcoma or liposarcoma. Pembrolizumab was well-tolerated, with 56% of patients experiencing grade 3/4 adverse events, and no grade 5 events reported, indicating an acceptable safety profile.
Early Diagnosis and Treatment Are Critical in Achieving the Best Outcomes in Sarcoma, Kyle Doherty, OncLive, January 16, 2025. Breelyn Wilky, MD, discusses the importance of disease screening and early diagnosis in the treatment of patients with sarcoma.
Lete-Cel Receives FDA Breakthrough Therapy Designation for Advanced Myxoid/Round Cell Liposarcoma, Ashley Chan, OncLive, January 16, 2025. Key Takeaways – The trial’s primary endpoints included overall response rate, with secondary endpoints like time to response, disease control rate, and progression-free survival. Letetresgene autoleucel (lete-cel) received FDA breakthrough therapy designation for MRCLS after anthracycline-based chemotherapy, based on promising phase 2 trial results. The IGNYTE-ESO trial reported a 42% overall response rate in patients with synovial sarcoma or MRCLS, with a median response duration of 12.2 months. Safety findings were consistent with known profiles, with cytopenias, cytokine release syndrome, and rash as common adverse effects
OST-HER2 Meets Primary End Point of Phase 2b Trial in Lung-Only Metastatic Osteosarcoma, Kristi Rosa, OncLive, January 16, 2025. Key Takeaways – The 1-year OS rate with OST-HER2 was 91%, compared to 81% with historical controls, indicating a trend towards improved survival. OST-HER2 achieved a 33% 12-month EFS rate, surpassing the 20% rate of historical controls, with statistical significance (P = .0158). The phase 2b trial included patients aged 12-39 with fully resected, lung-only metastatic osteosarcoma, meeting specific inclusion criteria.OST-HER2 has received rare pediatric disease, fast track, and orphan drug designations from the FDA and European Medicines Agency.
2024
Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version –
NCI PDQ Summaries for Patients
– General Information About Childhood Soft Tissue Sarcoma
– Histopathological Classification of Childhood Soft Tissue Sarcoma
– Staging and Grading Systems for Childhood Soft Tissue Sarcoma
– Treatment Option Overview for Childhood Soft Tissue Sarcoma
– Special Considerations for the Treatment of Children With Soft Tissue Sarcoma
– Treatment of Newly Diagnosed Childhood Soft Tissue Sarcoma
– Treatment of Metastatic Childhood Soft Tissue Sarcoma
– Treatment of Progressive or Recurrent Childhood Soft Tissue Sarcoma
– Changes to This Summary (10/24/2022)
– About This PDQ Summary
ASCO GUIDELINES UPDATE ON PALLIATIVE CARE – 2024 Palliative Care for Patients With Cancer: ASCO Guideline Update | Journal of Clinical Oncology (ascopubs.org) – In 2012, the ASCO released a provisional clinical opinion on the timing and use of palliative care services for people with cancer. The report recommended that palliative care be combined with standard oncologic practice early in the disease course in order to improve quality of life for cancer survivors.
Proteomic profiling improves prognostic risk stratification of the Sarculator nomogram in soft tissue sarcomas of the extremities and trunk wall, Madhumeeta Chadha, Sara Iadecola, Andrew Jenks, Valeriya Pankova, Yuen Bun Tam, Jessica Burns, Amani Arthur, Christopher P. Wilding, Liang Chen, Priya Chudasama, Dario Callegaro, Dirk C. Strauss, Khin Thway, Alessandro Gronchi, Robin L. Jones, Rosalba Miceli, Sandro Pasquali, Paul H. Huang, Wiley Online Library, Cancer Medicine, Open Access, 23 July 2024.
Immunotherapy in Sarcoma: Current Data and Promising Strategies, Georgina E. Wood, MD, PhD, Christian Meyer, MD, Florent Petitprez, PhD, and Sandra P. D’Angelo, MD, Society of Clinical Oncology Educational Book, Volume 44, Number 3.
Leveraging Patient Engagement Through Collaboration for Improved Global Health Outcomes in Sarcoma, Denisse Evans, MSc, Sara Rothschild, MPH, Carol Tordella, and Matías Chacón, MD, American Society of Clinical Oncology Educational Book, Volume 44, Number 3.
Immunotherapy in Sarcoma: Current Data and Promising Strategies, Georgina E. Wood, MD, PhD, Christian Meyer, MD, Florent Petitprez, PhD, and Sandra P. D’Angelo, MD, American Society of Clinical Oncology Educational Book, Volume 44, Number 3.
Sarcoma incidence worldwide: regional differences in histology and molecular subtypes, Lee MJ, Chen TW, Curr Opin Oncol. 2024 Apr 26. doi: 10.1097/CCO.0000000000001046. Epub ahead of print. PMID: 38726812.
What Is a Sarcoma ‘Specialist Center’? Multidisciplinary Research Finds an Answer, Wilson R, Reinke D, van Oortmerssen G, Gonzato O, Ott G, Raut CP, Guadagnolo BA, Haas RLM, Trent J, Jones R, et al. What Is a Sarcoma ‘Specialist Center’? Multidisciplinary Research Finds an Answer. Cancers. 2024; 16(10):1857.
Surgical resection of retroperitoneal sarcoma, updated 1/2/2024, William Tseng, MD.
Making the Decision to Enroll in a Clinical Trial – Chondrosarcoma Foundation, 2024.
Best Overall Response-associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE, Liu J, Moura DS, Jones RL, Aggarwal A, Philip EJ, Wagner AJ, Wright J, Martín-Broto J, Tap WD, Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3936. Epub ahead of print. PMID: 38536068.
2023
The emerging role of immunotherapy for the treatment of sarcoma, Nicholas D Klemen, Ciara M Kelly, Edmund K Bartlett, J Surg Oncol. 2021 Mar;123(3):730-738. doi: 10.1002/jso.26306. Epub 2020 Dec 1. PMID: 33259653; PMCID: PMC9212861.
Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors, Xu Y, Shi F, Zhang Y, Yin M, Han X, Feng J, Wang G. x Int J Cancer. 2024 Jan 15;154(2):226-240. doi: 10.1002/ijc.34694. Epub 2023 Aug 19. PMID: 37596989.
Rapid Classification of Sarcomas Using Methylation Fingerprint: A Pilot Study, Iluz A, Maoz M, Lavi N, Charbit H, Or O, Olshinka N, Demma JA, Adileh M, Wygoda M, Blumenfeld P, Gliner-Ron M, Azraq Y, Moss J, Peretz T, Eden A, Zick A, Lavon I., Cancers (Basel). 2023 Aug 18;15(16):4168. doi: 10.3390/cancers15164168. PMID: 37627196; PMCID: PMC10453223.
The protemic landscape. of soft tissue sarcoma, Burns, J., Wilding, C.P., Krasny, L. et al., Nat Commun 14, 3834 (2023). https://doi.org/10.1038/s41467-023-39486-2
New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas, Gyuhee Seong, Sandra P. D’Angelo, Front. Oncol., 13 March 2023, Sec. Molecular and Cellular Oncology
Volume 13 – 2023 | https://doi.org/10.3389/fonc.2023.1150765
NCCN Information for all sarcoma subtypes:
NCCN Patient Guidelines for Soft Tissue Sarcoma
NCCN Guidelines for Bone Sarcoma
Non-coding RNAs in metabolic reprogramming of bone and soft tissue sarcoma: Fundamental mechanism and clinical implication, Huan-Huan Chen , Peng-Hui Hao, Fang-Yuan Zhang, Tie-Ning Zhang, Science Direct, Elsevier, Biomedicine & Pharmacotherapy, Vol. 160, April 2023
Prognostic impact of circulating tumor cells in patients with soft-tissue sarcomas: a prospective study, Julie Blanchi, Audrey Laroche-Clary, François Le Loarer, Benjamin Bonhomme, Antoine Italiano, Cancer Communications, February 3, 2023, (DOI: 10.1002/cac2.12389)
High-Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations
Josephine K. Dermawan, Sarah Chiang, Martee L. Hensley, William D. Tap, Cristina R. Antonescu, Science Direct, Elsevier, Modern Pathology, Vol. 36, Issue 5, originally published January 23, 2023 (DOI:https://doi.org/10.1016/j.modpat.2023.100104).
2022
Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas, William G. J. Kerrison, Alexander T. J. Lee, Khin Thway, Robin L. Jones, Paul H. Huang, Emmy D. G. Fleuren, Biomedicines, February 28, 2023 (doi: 10.3390/biomedicines10030573)